Use of gene expression profiling to predict survival in cancer patient
AssigneeBoard of Trustees of the University of Arkansas
InventorsJohn D. Shaughnessy, Bart Barlogie, Fenghuang Zhan
Life of this patent
Estimating the term…
Abstract
Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.
Claims4
A method of determining the prognosis of a multiple myeloma patient, comprising the steps of:
- obtaining plasma cells from said patient;
- and
- determining copy number of CKS1B gene in the plasma cell, wherein increased copy number of said gene compared to copy number of the same gene in a plasma cell of a control individual indicates that said patient would have a poor prognosis indicating high risk of relapse in said patient after treatment.
Dependencies are inferred from the claim text.